logo-loader
HealthPharma & Biotech
ANGLE PLC

ANGLE scores early success in ovarian cancer study

The so-called pre-study used the company’s Parsortix system in harness with a system called HyCEADTM Ziplex to assess women with pelvic masses

ovarian cancer graphic
Between 5% and 10% of women present had a pelvic mass, with 13% to 21% of them being diagnosed with ovarian cancer

ANGLE PLC (LON:AGL) said the early phase of a clinical verification process for its liquid biopsy system as a test for ovarian cancer has reported positive results.

The so-called pre-study used the company’s Parsortix technology in harness with a system called HyCEADTM Ziplex to assess women with pelvic masses.

A total of 26 had stage III or IV cancer, while 28 were healthy. The test revealed there was high sensitivity – in other words the combination correctly detected the cancer. At the same time it was effective in identifying those that didn’t have the disease. So the potential for a false positive was minimised.

Larger study

The results pave the way for a clinical verification study of 200 women scheduled for pelvic mass surgery, which is expected to get underway in the third quarter and should report in the first three months of next year.

Success with this far larger assessment would then allow ANGLE to launch an assay to assess woman with abnormal pelvic masses.

"The performance of ANGLE's optimised sample-to-answer molecular solution for ovarian cancer in the pre-study is encouraging,” said the med-tech firm’s chief executive, Andrew Newland. 

“We are excited about progressing the full clinical verification study which will help support the launch of a clinical assay at a clinical laboratory and/or via a commercial partnership."

U$1bn market 

The latest work was carried out by Dr Richard Moore and his team at the University of Rochester Medical Center, Upstate New York.

Between 5% and 10% of women present had a pelvic mass, with 13% to 21% of them being diagnosed with ovarian cancer. 

A test to detect circulating tumour cells in the blood and hence ovarian cancer prior to surgery would enable women to be “triaged” to appropriate surgical procedures, improving patient outcomes whilst at the same time reducing overall healthcare costs. 

ANGLE estimates that the global market size for this clinical application is worth US$1bn a year.

In a note to clients, analysts at ‘house; broker finnCap said: “A positive outcome would support ANGLE’s plans to launch a clinical assay for the detection of ovarian cancer in women with an abnormal pelvic mass at a clinical laboratory and/or via a commercial partnership.”

They reiterated a 130p target valuation for ANGLE shares which in late morning trading were changing hands at 67p each.

 -- Adds analyst comment, share price --

Quick facts: ANGLE PLC

Price: £0.71

Market: AIM
Market Cap: £121.79 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of ANGLE PLC named herein, including the promotion by the Company of ANGLE PLC in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

2 min read